Defronzo RA: Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009, 58: 773-795. 10.2337/db09-9028.
Article
CAS
PubMed
PubMed Central
Google Scholar
Moller DE, Flier JS: Insulin resistance–mechanisms, syndromes, and implications. N Engl J Med. 1991, 325: 938-948. 10.1056/NEJM199109263251307.
Article
CAS
PubMed
Google Scholar
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F: European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 2012, 19: 403-488. 10.1007/s12529-012-9242-5.
Article
PubMed
Google Scholar
Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, De Boer MJ, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, et al: Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007, 28: 88-136.
Article
CAS
PubMed
Google Scholar
Lehman R, Yudkin JS, Krumholz H: Licensing drugs for diabetes. BMJ. 2010, 341: c4805-10.1136/bmj.c4805.
Article
PubMed
Google Scholar
Khan SS, Butler J, Gheorghiade M: Management of comorbid diabetes mellitus and worsening heart failure. JAMA. 2014, 311: 2379-2380. 10.1001/jama.2014.4115.
Article
CAS
PubMed
Google Scholar
Blind E, Dunder K, De Graeff PA, Abadie E: Rosiglitazone: a European regulatory perspective. Diabetologia. 2011, 54: 213-218. 10.1007/s00125-010-1992-5.
Article
CAS
PubMed
Google Scholar
US Food and Drug Administration: FDA requires removal of certain restrictions on the diabetes drug Avandia. November 25, 2013
Shehadeh A, Regan TJ: Cardiac consequences of diabetes mellitus. Clin Cardiol. 1995, 18: 301-305. 10.1002/clc.4960180604.
Article
CAS
PubMed
Google Scholar
Goyal A, Norton CR, Thomas TN, Davis RL, Butler J, Ashok V, Zhao L, Vaccarino V, Wilson PW: Predictors of incident heart failure in a large insured population: a one million person-year follow-up study. Circ Heart Fail. 2010, 3: 698-705. 10.1161/CIRCHEARTFAILURE.110.938175.
Article
PubMed
PubMed Central
Google Scholar
Joffe SW, Webster K, McManus DD, Kiernan MS, Lessard D, Yarzebski J, Darling C, Gore JM, Goldberg RJ: Improved survival after heart failure: a community-based perspective. J Am Heart Assoc. 2013, 2: e000053-
Article
PubMed
PubMed Central
Google Scholar
Mosterd A, Cost B, Hoes AW, De Bruijne MC, Deckers JW, Hofman A, Grobbee DE: The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J. 2001, 22: 1318-1327. 10.1053/euhj.2000.2533.
Article
CAS
PubMed
Google Scholar
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000, 321: 405-412. 10.1136/bmj.321.7258.405.
Article
CAS
PubMed
PubMed Central
Google Scholar
Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV: Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001, 103: 2668-2673. 10.1161/01.CIR.103.22.2668.
Article
CAS
PubMed
Google Scholar
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012, 35: 1364-1379. 10.2337/dc12-0413.
Article
CAS
PubMed
PubMed Central
Google Scholar
US Food and Drug Administration: Information for healthcare professionals: pioglitazone HCl (marketed as Actos, Actoplus Met, and Duetact). 2007
Google Scholar
Takeda Pharmaceuticals America, Inc: Actos (pioglitazone) tablets for oral use [package insert]. 2013
Google Scholar
US Food and Drug Administration: FDA adds boxed warning for heart-related risks to anti-diabetes drug Avandia. November 14, 2007
Google Scholar
GlaxoSmithKline: Avandia (rosiglitazone maleate) tablets [package insert]. 2007
Google Scholar
Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA: Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007, 335: 497-10.1136/bmj.39314.620174.80.
Article
CAS
PubMed
PubMed Central
Google Scholar
Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, Vanderloo SE, McAlister FA: Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013, 6: 395-402. 10.1161/CIRCHEARTFAILURE.112.000162.
Article
CAS
PubMed
Google Scholar
Norwood DK, Chilipko AA, Amin SM, Macharia D, Still KL: Evaluating the potential benefits of metformin in patients with cardiovascular disease and heart failure. Consult Pharm. 2013, 28: 579-583. 10.4140/TCP.n.2013.579.
Article
PubMed
Google Scholar
Loke YK, Kwok CS, Singh S: Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011, 342: d1309-10.1136/bmj.d1309.
Article
PubMed
PubMed Central
Google Scholar
Chen X, Yang L, Zhai SD: Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies. Chin Med J (Engl). 2012, 125: 4301-4306.
Google Scholar
Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S: Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011, 154: 602-613. 10.7326/0003-4819-154-9-201105030-00336.
Article
PubMed
PubMed Central
Google Scholar
Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. Section 13.5.2.3. Tools for Assessing Methodological Quality or Risk of Bias in Non-randomized Studies. 2011, London: The Cochrane Collaboration
Google Scholar
Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011
Google Scholar
Viswanathan M, Berkman ND: Development Of The RTI Item Bank On Risk Of Bias And Precision Of Observational Studies. 2011, Rockville (MD): Agency for Healthcare Research and Quality
Google Scholar
Viswanathan M, Berkman ND: Development of the RTI item bank on risk of bias and precision of observational studies. J Clin Epidemiol. 2012, 65: 163-178. 10.1016/j.jclinepi.2011.05.008.
Article
PubMed
Google Scholar
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2.
Article
CAS
PubMed
Google Scholar
The Cochrane Collaboration: Cochrane handbook for systematic reviews of interventions, version 5.1.0. March 2011
Google Scholar
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000, 283: 2008-2012. 10.1001/jama.283.15.2008.
Article
CAS
PubMed
Google Scholar
Chou CC, Chen WL, Kao TW, Chang YW, Loh CH, Wang CC: Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Clin Ther. 2011, 33: 1904-1913. 10.1016/j.clinthera.2011.10.025.
Article
CAS
PubMed
Google Scholar
Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA: Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010, 304: 411-418. 10.1001/jama.2010.920.
Article
CAS
PubMed
Google Scholar
Horsdal HT, Johnsen SP, Sondergaard F, Rungby J: Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. Diabetologia. 2008, 51: 567-574. 10.1007/s00125-008-0947-6.
Article
CAS
PubMed
Google Scholar
Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW: Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf. 2009, 32: 675-690. 10.2165/00002018-200932080-00006.
Article
CAS
PubMed
Google Scholar
Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM: Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009, 339: b2942-10.1136/bmj.b2942.
Article
PubMed
PubMed Central
Google Scholar
Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM: Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med. 2005, 22: 986-993. 10.1111/j.1464-5491.2005.01704.x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Koro CE, Bowlin SJ, Weiss SR: Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiol Drug Saf. 2005, 14: 697-703. 10.1002/pds.1069.
Article
CAS
PubMed
Google Scholar
Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, Kurnik D, Lomnicky Y, Kokia E, Halkin H: Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes. J Clin Pharmacol. 2011, 51: 173-180. 10.1177/0091270010368281.
Article
CAS
PubMed
Google Scholar
McAlister FA, Eurich DT, Majumdar SR, Johnson JA: The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail. 2008, 10: 703-708. 10.1016/j.ejheart.2008.05.013.
Article
CAS
PubMed
Google Scholar
Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009, 339: b4731-10.1136/bmj.b4731.
Article
PubMed
PubMed Central
Google Scholar
Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL: Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes. 2010, 3: 538-545. 10.1161/CIRCOUTCOMES.109.911461.
Article
PubMed
Google Scholar
Winkelmayer WC, Setoguchi S, Levin R, Solomon DH: Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 2008, 168: 2368-2375. 10.1001/archinte.168.21.2368.
Article
PubMed
Google Scholar
Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS: Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003, 26: 2983-2989. 10.2337/diacare.26.11.2983.
Article
CAS
PubMed
Google Scholar
Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall M, Williams LK: Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf. 2009, 18: 437-447. 10.1002/pds.1722.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hartung DM, Touchette DR, Bultemeier NC, Haxby DG: Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a Medicaid claims-based case–control study. Pharmacotherapy. 2005, 25: 1329-1336. 10.1592/phco.2005.25.10.1329.
Article
CAS
PubMed
Google Scholar
Horsdal HT, Johnsen SP, Sondergaard F, Jacobsen J, Thomsen RW, Schmitz O, Sorensen HT, Rungby J: Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev. 2009, 25: 515-522. 10.1002/dmrr.971.
Article
CAS
PubMed
Google Scholar
Hsiao FY, Tsai YW, Wen YW, Chen PF, Chou HY, Chen CH, Kuo KN, Huang WF: Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan. Pharmacoepidemiol Drug Saf. 2010, 19: 786-791. 10.1002/pds.1999.
Article
CAS
PubMed
Google Scholar
Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA: Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007, 298: 2634-2643. 10.1001/jama.298.22.2634.
Article
CAS
PubMed
Google Scholar
Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT: Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther. 2004, 26: 1400-1410. 10.1016/j.clinthera.2004.09.016.
Article
CAS
PubMed
Google Scholar
Toprani A, Fonseca V: Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. Diabetes Obes Metab. 2011, 13: 276-280. 10.1111/j.1463-1326.2010.01348.x.
Article
CAS
PubMed
Google Scholar
Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, Viswanathan M, Perez-Gutthann S: Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014, 6: 1-10.
Google Scholar
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013, 369: 1317-1326. 10.1056/NEJMoa1307684.
Article
CAS
PubMed
Google Scholar
Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT: Sitagliptin Use in Patients With Diabetes and Heart Failure: A Population-Based Retrospective Cohort Study. 2014, Europe: JACC Heart Fail
Google Scholar
Singh S, Loke YK, Furberg CD: Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007, 30: 2148-2153. 10.2337/dc07-0141.
Article
CAS
PubMed
Google Scholar
Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA, investigators PR: Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007, 30: 2773-2778. 10.2337/dc07-0717.
Article
CAS
PubMed
Google Scholar
Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD: Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010, 31: 824-831. 10.1093/eurheartj/ehp604.
Article
CAS
PubMed
PubMed Central
Google Scholar
Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA: A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006, 333: 15-10.1136/bmj.38875.675486.55.
Article
PubMed
PubMed Central
Google Scholar
Ray WA: Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003, 158: 915-920. 10.1093/aje/kwg231.
Article
PubMed
Google Scholar
Suissa S: Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007, 16: 241-249. 10.1002/pds.1357.
Article
PubMed
Google Scholar
Lee DS, Donovan L, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV: Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005, 43: 182-188. 10.1097/00005650-200502000-00012.
Article
PubMed
Google Scholar
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Task Force for the Diagnosis, Treatment of Acute, Chronic Heart Failure 2012 of the European Society of Cardiology, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012, 14: 803-869.
Article
CAS
PubMed
Google Scholar
UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998, 352: 854-865.
Article
Google Scholar
Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology. 2000, 11: 550-560. 10.1097/00001648-200009000-00011.
Article
CAS
PubMed
Google Scholar
Gallagher AM, Smeeth L, Seabroke S, Leufkens HG, Van Staa TP: Correction: Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the General Practice Research Database and secondary care data. PLoS ONE. 2013, 8:
Google Scholar
Tannen R, Xie D, Wang X, Yu M, Weiner MG: A new “Comparative Effectiveness” assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. Pharmacoepidemiol Drug Saf. 2013, 22: 86-97. 10.1002/pds.3360.
Article
CAS
PubMed
Google Scholar
Breunig IM, Shaya FT, McPherson ML, Snitker S: Development of heart failure in medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin. J Manag Care Pharm. 2014, 20: 895-903.
Google Scholar
Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY: Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovasc Dis. 2013, 36: 145-151. 10.1159/000353679.
Article
CAS
PubMed
Google Scholar
Romero SP, Andrey JL, Garcia-Egido A, Escobar MA, Perez V, Corzo R, Garcia-Domiguez GJ, Gomez F: Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community. Int J Cardiol. 2013, 166: 404-412. 10.1016/j.ijcard.2011.10.141.
Article
PubMed
Google Scholar
Roussel R, Hadjadj S, Pasquet B, Wilson PW, Smith SC, Goto S, Tubach F, Marre M, Porath A, Krempf M, Bhatt DL, Steg PG: Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality. Int J Cardiol. 2013, 167: 1380-1384. 10.1016/j.ijcard.2012.04.019.
Article
PubMed
Google Scholar